A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients

Exclusion Criteria

• •1. Hypersensitivity or allergy to the investigational medicinal product (IMP) or to chemically related products
• •2. Contraindications for the use of levodopa or carbidopa or entacapone
• •3. Needing a daily total dose of Duodopa during study participation exceeding 125 mL
• •4. Increased fluctuation in clinical PD symptoms within 7 days prior to Screening
• •5. Administration of an investigational drug within 3 months prior to Screening and/or current participation in another clinical study involving a pharmaceutical or a medical device class III
• •6. Use of any forbidden medication as specified in Section 9.6 of the protocol
• •7. Known hepatitis B, hepatitis C or HIV infection
• •8. Donation of blood or plasma or major blood loss (≥500 mL) within 3 months prior to Screening
• •9. Positive urine drug test (amphetamine, benzodiazepines, tetrahydrocannabinol, cocaine or opiates) at Screening
• •10. Known alcohol abuse
• •11. Unwilling to meet the requirements of the protocol
• •12. Other medical or social reasons for exclusion at the discretion of the Investigator